Tvardi Therapeutics (NASDAQ:TVRD) Now Covered by Chardan Capital

Stock analysts at Chardan Capital began coverage on shares of Tvardi Therapeutics (NASDAQ:TVRD) in a research note issued on Tuesday, Marketbeat Ratings reports. The brokerage set a “buy” rating on the stock.

Several other equities analysts have also weighed in on TVRD. Lucid Cap Mkts raised shares of Tvardi Therapeutics to a “strong-buy” rating in a report on Tuesday, September 8th. BTIG Research cut their target price on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, October 2nd. Wall Street Zen lowered shares of Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, October 12th. Finally, Raymond James Financial raised shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Tvardi Therapeutics has an average rating of “Moderate Buy” and an average target price of $9.40.

Tvardi Therapeutics Price Performance

TVRD traded up $0.05 during trading on Tuesday, reaching $1.02. 44,961 shares of the company’s stock were exchanged, compared to its average volume of 794,698. The stock has a market capitalization of $13.54 million, a P/E ratio of -0.36 and a beta of 0.38. Tvardi Therapeutics has a 1 year low of $0.93 and a 1 year high of $6.13. The company’s fifty day simple moving average is $1.55 and its 200-day simple moving average is $2.46.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Equities analysts forecast that Tvardi Therapeutics will post -2.35 EPS for the current year.

Hedge Funds Weigh In On Tvardi Therapeutics

Several institutional investors have recently made changes to their positions in TVRD. GSA Capital Partners LLP purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at approximately $34,000. Susquehanna International Group LLP purchased a new stake in Tvardi Therapeutics in the 2nd quarter worth $63,000. Finally, BlackRock Inc. purchased a new stake in Tvardi Therapeutics in the 2nd quarter worth $181,000. 44.66% of the stock is owned by hedge funds and other institutional investors.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing.